drugset / Trial / NCT01484015
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia
Phase 1
Completed
70 enrolled
Wake Forest University Health Sciences
National Cancer Institute (NCI) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This randomized pilot clinical trial studies how well giving prolonged infusion compared to standard infusion of cefepime hydrochloride works in treating patients with febrile neutropenia. Giving cefepime hydrochloride over a longer period of time may be more effective than giving cefepime hydrochloride over the standard time.
Timeline
- Start
- 2011-02
- Primary completion
- 2012-06
- Completion
- 2012-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cefepime | Small molecule | — | Intravenous |
Indications
Burkitt lymphoma
Hodgkins lymphoma
MALT lymphoma
acute myeloid leukemia
adult acute lymphoblastic leukemia
atypical chronic myeloid leukemia, BCR-ABL1 negative
breast cancer
chronic eosinophilic leukemia
chronic lymphocytic leukemia/small lymphocytic lymphoma
chronic myeloid leukemia
chronic myelomonocytic leukemia
chronic neutrophilic leukemia
diffuse large B-cell lymphoma
gestational trophoblastic neoplasm
large-cell immunoblastic lymphoma
malignant epithelial tumor of ovary
malignant testicular germ cell tumor
mantle cell lymphoma
mycosis fungoides and variants
myelodysplastic syndrome
neuroblastoma
neutropenia
nodal marginal zone B-cell lymphoma
ovarian germ cell tumor
plasma cell myeloma
primary cutaneous T-cell non-Hodgkin lymphoma
primary myelofibrosis
prolymphocytic leukemia
splenic marginal zone lymphoma